- Aytu acquires Innovus in cash & stock transaction making a total deal value up to $24M. Innovus to receive up to $8M shares in Aytu’s common stock as upfront after deducting $1M principal amount promissory note, warrants, liabilities, working capital, and other adjustments with ~$16M CVRs as milestones in next 5yrs.
- The acquisition will expand Aytu’s consumer healthcare market with the addition of 30+ product focusing diabetes, men’s health, sexual wellness and respiratory health. The combination of specialty Rx and consumer healthcare business is expected to generate $31M revenue
- The transaction is expected to be closed in Q2’20. The prescription product portfolio will continue to commercialize via Aytu’s sales force while consumer health products will commercialize via Innovus’ Beyond Human marketing platform
Click here to read full press release/ article | Ref: Aytu Bioscience | Image: Innovus Pharmaceutical